Exploratory trial of a combination therapy of Gemcitabine, S1 and immunotherapy against pancreatic cancer.

Not Applicable

• Conditions: pancreatic cancer

• Registration Number: JPRN-UMIN000027565
• Lead Sponsor: Department of Gastroenterology and Hepatology, School of Medicine, Kochi University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with uncontrollable infectious diseases (including active Tuberculosis) 2) patients with severe complications (malignant lypertension, severe congestive heart failure, severe colonary in sufficiency, myocardial, infarction within three months, terminal, stage of liver cirrhousis, uncontrollable diabetes mellitus, severe pulmonary fibrosis, active interstitial pneumonitis, etc.) 3) patients with serious comorbidities (generally those of NCI-CTC ver 3.0 grade 3 or higher) 4) patients who have been under parenteral nutrition for more than 24 hours due to impairment of digestive organs. 5) liver metastasis occupying more than 1/3 of the liver 6) Patients with active concomitant malignancy 7) patients with hematopoietic malignancies including MDS, MDS/MPD, CML 8) patients who have received bone marrow or hematopoietic stem cell transplantation 9) pregnant women, breast feeding mothers 10) patients with serious psychological disorders 11) patients whose participation to the study is considered inappropriate by the doctors for various reasons.

Study & Design

• Study Type: Interventional
• Study Design: Not specified